Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2020-0063
Abstract: Aim: To perform indirect treatment comparisons of entrectinib versus alternative ROS1 fusion-positive non-small cell lung cancer treatments. Methods: Relevant studies with crizotinib and chemotherapy as comparators of interest identified by systematic literature review were selected… read more here.
Keywords: versus crizotinib; ros1 fusion; positive non; non small ... See more keywords